MedTrace Logo

Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects

NCT02609139 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-05-09

No results posted yet for this study

Summary

This is a Phase 1, open-label, single-dose, within-cohort randomized, 2-way crossover study to evaluate the PK of orally administered PF-06650833 modified release tablets under fasted and high fat meal fed conditions in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

PF-06650833

Up to 400mg modified release tablets administered under fasted conditions

DRUG

PF-06650833

100mg modified release tablet administered under fasted conditions

DRUG

PF-06650833

20mg modified release tablet administered under fasted conditions

DRUG

PF-06650833

Up to 400mg modified release tablets administered with high fat meal food intake

DRUG

PF-06650833

100mg modified released tablet administered with high fat meal food intake

DRUG

PF-06650833

20 mg modified release tablet administered with high fat meal food intake

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609139 on ClinicalTrials.gov